aTyr Pharma Publishes Preclinical ATYR0101 Anti-Fibrosis Data Ahead of Planned 2027 Clinical Entry
aTyr Pharma, Inc. (ATYR) has published preclinical study results in the Journal of Biological Chemistry evaluating its proprietary drug candidate ATYR0101. In vivo testing demonstrated anti-fibrotic effects, benchmarking the therapeutic candidate against a nintedanib control.
The peer-reviewed research offers scientific validation for ATYR0101 as a potential treatment for fibrotic diseases. Despite the positive preclinical findings, shares of aTyr Pharma fell 12.75% to $0.2148 in recent market action.
The program is currently undergoing investigational new drug enabling studies. Future milestones for the candidate include filing an IND and initiating Phase 1 human trials, which the company expects to begin in 2027.
Key points
- aTyr Pharma published preclinical data on ATYR0101 in the Journal of Biological Chemistry.
- In vivo testing showed anti-fibrotic effects when compared to a nintedanib control.
- ATYR0101 is in IND-enabling studies with entry into human clinical trials anticipated in 2027.
- Shares of aTyr Pharma (ATYR) fell 12.75% to $0.2148 following the announcement.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What preclinical data did aTyr Pharma publish for ATYR0101?
aTyr Pharma published peer-reviewed data in the Journal of Biological Chemistry showing that ATYR0101 demonstrated anti-fibrotic effects in vivo compared to a nintedanib control.
When is ATYR0101 expected to enter clinical trials?
The program is currently undergoing IND-enabling studies, with entry into human clinical trials targeted for 2027.
How did aTyr Pharma stock perform following the news?
Shares of aTyr Pharma, Inc. (ATYR) dropped 12.75% to $0.2148 following the update.